Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · Real-Time Price · USD

108.17

+2.05 (1.93%)

At close: Aug 21, 2026, 4:00 PM EDT

108.40

+0.23 (0.21%)

After-hours: Aug 21, 2026, 7:20 PM EDT

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	12,277	7,914	6,083	4,882	7,694	5,659
Market Cap Growth	49.99%	30.11%	24.59%	-36.54%	35.96%	-1.84%
Enterprise Value	14,225	8,751	6,951	5,929	8,940	5,722
Last Close Price	106.12	67.30	47.81	36.96	56.90	40.21

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	31.98	24.98	13.70	17.34	38.06	14.05
Forward PE	11.04	8.85	10.38	9.77	21.92	17.89
PS Ratio	7.35	5.67	5.99	5.89	11.66	12.76
PB Ratio	84.31	162.13	16.72	58.26	45.31	28.73
P/TBV Ratio	-	-	-	-	-	28.73
P/FCF Ratio	15.18	12.28	12.99	13.08	32.70	18.99
P/OCF Ratio	14.95	12.15	12.70	12.57	32.04	18.90
PEG Ratio	-	0.55	0.55	0.90	0.91	0.46

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	8.52	6.27	6.85	7.15	13.54	12.91
EV/EBITDA Ratio	13.50	9.75	11.09	14.22	26.60	20.63
EV/EBIT Ratio	15.02	10.72	12.61	17.56	30.89	20.74
EV/FCF Ratio	17.59	13.58	14.84	15.88	37.99	19.20

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	15.18	44.60	4.14	18.27	9.07	4.47
Debt / EBITDA Ratio	2.05	2.40	2.38	3.59	4.54	3.15
Debt / FCF Ratio	2.70	3.38	3.22	4.10	6.55	2.95
Net Debt / Equity Ratio	13.57	41.68	2.50	14.26	6.94	0.70
Net Debt / EBITDA Ratio	1.85	2.27	1.45	2.87	3.51	0.50
Net Debt / FCF Ratio	2.42	3.16	1.94	3.20	5.01	0.47
Asset Turnover	0.72	0.61	0.54	0.46	0.45	0.53
Inventory Turnover	2.48	1.95	1.77	2.36	2.67	2.04
Quick Ratio	1.99	3.30	6.50	5.07	4.54	7.10
Current Ratio	2.71	4.66	7.80	6.64	5.65	7.91
Return on Equity (ROE)	173.67%	153.59%	198.42%	222.07%	110.23%	231.44%
Return on Assets (ROA)	25.49%	22.24%	18.16%	11.80%	12.28%	20.47%
Return on Invested Capital (ROIC)	32.13%	33.01%	34.44%	20.77%	27.92%	105.98%
Return on Capital Employed (ROCE)	42.30%	34.80%	28.70%	20.80%	16.90%	27.90%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	3.38%	4.00%	7.30%	5.77%	2.63%	7.12%
FCF Yield	6.59%	8.14%	7.70%	7.65%	3.06%	5.27%
Buyback Yield / Dilution	4.21%	4.26%	3.56%	4.56%	4.21%	-3.77%

SEC Filings: 10-K · 10-Q